Gastric Intestinal Metaplasia: Prevalence, Clinical Presentation, Endoscopic and Histological Features

Open access

Abstract

Background and Aim: Gastric intestinal metaplasia represents a risk factor for intestinal type of gastric cancer. Gastric intestinal metaplasia seems to be associated with Helicobacter pilory infection in relatives of patients with gastric cancer. The aim of this study was to determine the prevalence, clinical, endoscopic and histological features of gastric intestinal metaplasia.

Material and Methods: We retrospectively analyzed the esophagogastroduodenoscopies with biopsies performed between January 1, 2014 and October 31, 2014. Collected and analyzed data included age, gender, symptoms, endoscopic and histological findings.

Results: Four hundred eighty-two patients were included in the study. One hundred thirty-seven patients had gastric intestinal metaplasia, which presented a prevalence was 28,4%. A similar distribution between gender was observed with a significant increase of gastric intestinal metaplasia with age (p=0,0001). Regarding the indication for endoscopy, the prevalence of gastric intestinal metaplasia was: 17 % among patients with dyspeptic syndrome, 2 % in patients with anemia and 5 % in patients examined for other symptoms. Endoscopic findings showed gastric intestinal metaplasia was significantly associated with atrophic gastritis (p=0.0001), erythematous gastritis (p=0.0079), while there was no association with erosive gastritis (p=0.24) and peptic ulcer (p=0.19).

Conclusions: Gastric intestinal metaplasia is frequently recorded in patients undergoing in esophagogastroduodenoscopies with associated biopsies. Endoscopic findings like erythema and atrophy is strongly associated with gastric intestinal metaplasia emphasizing the importance of sampling biopsies.

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893-2917.

2. Correa P, Piazuelo M. The Gastric Precancerous Cascade. J Clin Exp Pathol. 2013;3 (3):147.

3. Lauren P.The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand.1965;64: 31-49.

4. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-first American Cancer Society award lecture on cancer epidemiology and prevention.Cancer research.1992;52:6735-6740.

5. González CA, Agudo A. Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer. 2012;130:745-753.

6. Zullo A, Hassan C, Romiti A, Giusto M, Guerriero C, Lorenzetti R, Campo SM, Tomao S. Follow-up of intestinal metaplasia in the stomach: When, how and why. World J Gastrointest Oncol. 2012;4:30-36.

7. Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JW. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut. 2002;50:378-381.

8. Park YH, Kim N. Review of Atrophic Gastritis and Intestinal Metaplasia as a Premalignant Lesion of Gastric Cancer. J Cancer Prev. 2015; 20:25-40.

9. Craanen, M. E.,Dekker W, Blok P et al. Intestinal metaplasia and Helicobacter pylori: an endoscopic bioptic study of the gastric antrum. Gut. 1992;33:16-20.

10. Joo YE, Park HK, Myung DS et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia: a nationwide multicenter prospective study in Korea. Gut Liver.2013;7:303-310.

11. Zullo A, Gatta L, De Francesco V, et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther. 2005;21:1419-1424.

12. Tulassay Z, Stolte M, Engstrand L, et al. Twelve-month endoscopic and histological analysis following proton-pump inhibitor-based triple therapy in Helicobacter pylori-positive patients with gastric ulcers. Scand J Gastroenterol. 2010;45:1048-1058.

13. Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut. 2004;53:1244-1249.

14. Eshmuratov A, Nah JC, Kim N, et al. The correlation of endoscopic and histologic

15. Den Hoed C. M., B.C. van Eijck, L.G. Capelle, et al. The prevalence of premalignant gastric lesions in asymptomatic patients: predicting the future incidence of gastric cancer. Eur J Cancer. 2011;47:1211-1218.

16. Sonnenberg A, Lash RH, Genta RM. A national study of Helicobactor pylori infection in gastric biopsy specimens.Gastroenterology. 2010;139:1894-1901.

17. Conteduca V, Sansonno D, Lauletta G, et al. H. pylori infection and gastric cancer: State of the art (Review). Int J Oncol. 2013;42:5-18.

18. Valle J, Gisbert JP. Helicobacter pylori infection and precancerous lesions of the stomach. Hepato-gastroenterology. 2000;48:1548-1551.

19. Haziri A, Juniku-Shkololli A, Gashi Z, et al. Helicobacter pylori infection and precancerous lesions of the stomach. Med Arh. 2010;64:248-249.

20. Zhang C, Yamada N, Wu YL, et al. Helicobacter pylori infection, glandular atrophy and intestinal metaplasia in superficial gastritis, gastric erosion, erosive gastritis, gastric ulcer and early gastric cancer. World J Gastroenterol. 2005;11:791-796.

21. Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48:3554-3560.

22. Rozen P. Cancer of the gastrointestinal tract: early detection or early prevention? Eur J Cancer Prev. 2004;13:71-75.

23. Israel DA, Peek RM. Review article: pathogenesis of Helicobacter pyloriinduced gastric inflammation. Aliment Pharmacol Ther. 2011;15:1271-1290.

Acta Medica Marisiensis

The Journal of The University of Medicine and Pharmacy of Targu-Mures

Journal Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 189 189 27
PDF Downloads 71 71 10